Subscribe
Be the first with the news that moves the market- Small Pharma (DMT) has had 2 patents approved by the U.S. Patent & Trademark Office to build up its portfolio
- One patent for a group of deuterated compounds of N, N-Dimethyltryptamine (DMT) was approved, as well as the composition of matter protection for certain deuterated homologues of certain tryptamine compounds
- The company’s total number of granted patents in its psychedelic and non-psychedelic portfolio now sits at 16, with more than 90 applications pending
- Small Pharma (DMT) is up 4.00 per cent, trading at C$0.13 at 12:55 pm ET
Small Pharma (DMT) has had two patents approved by the U.S. Patent & Trademark Office to further build up its portfolio.
One patent for a group of deuterated compounds of N, N-Dimethyltryptamine (DMT), as well as protection for therapeutic compositions and uses of specified compounds, was approved.
The company also received composition of matter protection for certain deuterated homologues of certain tryptamine compounds. The patent will also provide protection for therapeutic compositions of the deuterated tryptamines, including orally active formulations.
The company’s total number of granted patents in its psychedelic and non-psychedelic portfolio now sits at 16, with more than 90 applications pending.
George Tziras, Chief Executive Officer, said that innovating on known compounds has always been the foundation of the team’s vision.
“Building a robust IP position is central to protecting these innovations and allows our pipeline programs to develop towards a proprietary position in key markets, including the U.S. and Europe. Combined with the recent positive data from our Phase IIa trial for SPL026 in Major Depressive Disorder, our portfolio continues to strengthen in support of our mission to bring novel, scalable and reimbursable short-duration treatments to mental health patients.”
Small Pharma Inc. (DMT) is a biotechnology company progressing a pipeline of short-acting psychedelic-assisted therapies for the treatment of mental health conditions. The company’s current focus is on exploring new therapeutic approaches for depression.
Small Pharma (DMT) is up 4.00 per cent, trading at C$0.13 at 12:55 pm ET.
